# GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma

> **NCT03294954** · PHASE1 · RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 70 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **GENETIC:** GINAKIT Cells
- **BIOLOGICAL:** GINAKIT cells + Etanercept

## Key facts

- **NCT ID:** NCT03294954
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-01-18
- **Primary completion:** 2027-12
- **Final completion:** 2040-08-10
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03294954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03294954, "GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03294954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*